TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04799626

Intervention type: DRUG
Intervention: biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc
Description: biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc extended infusion time or continuous infusion for 24 hours;Tigecycline changed standard does for treatment.
Study: NCT06164925

Intervention type: DIAGNOSTIC_TEST
Intervention: Nutrition screening and assessment
Description: The patient is interviewed for changes in body weight in the last six months and food intake in the last two weeks.~The investigator evaluates the patient's diet, symptoms related to their nutritional status, and functional capacity according to the Subjective Global Assessment (SGA). The SGA tool itself is completed by the researcher.~Height and weight of the patient are measured, if not yet recorded, and BMI is calculated.~The patient's muscle mass is measured using mid-upper arm circumference (MUAC), calf circumference (CC) and bioelectrical impedance (BIA), and their muscle function assessed using hand grip strength.
Study: NCT05168891

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical therapy
Description: Peri-implantitis surgical therapy by means of open flap debridement, detoxification/decontamination of the implant surface and xenograft regeneration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical therapy of peri-implantitis
Description: Peri-implant non-surgical therapy combined with antibiotic regimen consisting on metronidazole 500 mg every 8 hours for 7 days will be performed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical therapy of peri-implantitis
Description: Peri-implant non-surgical therapy combined with antibiotic regimen consisting on metronidazole 500 mg every 8 hours for 7 days will be performed
Study: NCT06545422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: St. John's wort oil
Description: To examine the effect of regularly applied St. John's Wort oil on skin moisture.

Intervention type: OTHER
Group type: OTHER
Intervention: Barrier Cream
Description: To examine the effect of regularly applied barrier cream on skin moisture.
Study: NCT05774106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory action research
Description: First, a participatory intervention with nurses through the recording of four focus groups with the aim of understand, plan, change and maintain the practices surrounding the relationship therapy with their patients. Second, this intervention will be measured by administering scales to patients linked to the mental health case management program that provides service to different areas of the Barcelona Metropolitan Area. The variables to measure will be the quality of the therapeutic relationship, the recovery of the person and the overall functionality. These variables will be measured before and after finishing the participatory intervention.
Study: NCT06529315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point-of-Care Ultrasound
Description: The investigators will use point-of-care ultrasound to exam participants including lungs, heart, liver, spleen, kidney and bladder, etc.
Study: NCT06154382

Intervention type: DRUG
Intervention: Eltroxin administration
Description: eltroxin administration
Study: NCT04707274

Intervention type: OTHER
Intervention: Survey study
Description: Victorian Institute of Sports Assessment for Gluteal Tendinopathy (VISA-G) Questionnaire will be applied.
Study: NCT05466890

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PL8177 Placebo
Description: Approximately 1/4 of randomized patients will receive matching placebo as means of comparison to active treatment PL8177.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL8177
Description: Approximately 3/4 of randomized patients will receive active PL8177.
Study: NCT06230471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab,Lenvatinib and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）
Description: Drug: Pembrolizumab Pembrolizumab 200 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle. Drug: Lenvatinib Oral Product The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of \<60 kg, taken once daily. Drug: Chemotherapy GEMOX regimen: Gemcitabine 1000mg/m2 will be administered intravenously over 30 minutes on Day 1 and Day 8; Oxaliplatin 100mg/m2 will be administered intravenously over 2 hours on Day 1, and the cycle will be repeated every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and Lenvatinib
Description: Pembrolizumab and Lenvatinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）
Description: Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）
Study: NCT06530511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Polatuzumab: 1.8 mg/kg, IV Drip infusion, D1;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab: 375 mg/m2, IV Drip infusion, D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib: 150 mg/time, qd, po, D1-21
Study: NCT05241704

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafting
Description: Under general or local anaesthesia, fat will be harvested from either abdomen or lower limb. After harvesting the fat by liposuction, the lipoaspirate will be injected underneath the ulcer under complete aseptic operative setting

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovenous ablation of superficial venous reflux
Description: Endovenous ablation of the main truncal venous reflux to the lowest point of incompetence, where possible (routine practice)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous ablation of superficial venous reflux
Description: Endovenous ablation of the main truncal venous reflux to the lowest point of incompetence, where possible (routine practice)
Study: NCT05294796

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Short course of antibiotherapy
Description: Short duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Long course of antibiotherapy
Description: Long duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material
Study: NCT06579339

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: xylitol chewing gum
Description: Chewing gum with xylitol was chewed 3 times a day for 15 minutes. A new chewing gum was chewed by the researcher in each chewing period, chewing gum was stopped at the end of 15 minutes and each quadrant was listened for 15 seconds. The onset of bowel movement was evaluated and all information was recorded in the patient information form and follow-up form. Patients who were discharged without stool output were telephoned and their stool output was questioned. Gum chewing was performed at the 2nd hour, 4th hour and 6th hour postoperatively (due to the opening of the oral cavity at 6 hours) and the collection of patient data was continued by telephone until discharge and afterwards.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: xylitol chewing gum
Description: Chewing gum with xylitol was chewed 3 times a day for 15 minutes. A new chewing gum was chewed by the researcher in each chewing period, chewing gum was stopped at the end of 15 minutes and each quadrant was listened for 15 seconds. The onset of bowel movement was evaluated and all information was recorded in the patient information form and follow-up form. Patients who were discharged without stool output were telephoned and their stool output was questioned. Gum chewing was performed at the 2nd hour, 4th hour and 6th hour postoperatively (due to the opening of the oral cavity at 6 hours) and the collection of patient data was continued by telephone until discharge and afterwards.
Study: NCT05080946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325mg
Description: Participants will receive a tablet of 325mg aspirin that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a placebo tablet that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery.
Study: NCT05806229

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mid transverse process to pleura block (MTP)
Description: After marking the level of the incision by surgeon (commonly T11 -T12) The patient will be situated in modified lateral position with flank region over kidney elevated to wide the space between iliac crest and subcostal margin, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally lateral to the spinous process of T11 or T 12 and scanning till appearance of transverse process, 100-mm short bevel echogenic needle (Vygon) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura.After negative aspiration to avoid intravascular injection levobupivacaine 0.5% and dexamethazone 4mg total volume 21ml will be injected

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Mid transverse process to pleura Sham block
Description: After marking the level of the incision by surgeon (commonly T11 -T12) The patient will be situated in modified lateral position with flank region over kidney elevated to wide the space between iliac crest and subcostal margin, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally lateral to the spinous process of T11 or T 12 and scanning till appearance of transverse process, 100-mm short bevel echogenic needle (Vygon) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura. with 2ml normal saline subcutaneously will be injected
Study: NCT05109091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH434 dose level 1
Description: ATH434 taken BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH434 dose level 2
Description: ATH434 taken BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken BID
Study: NCT05275192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videoscope-assisted periodontal regeneration minimally invasive surgery
Description: Use of a videoscope to improve visualization of periodontal defect during minimally invasive surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal regeneration minimally invasive surgery
Description: Conventional periodontal regeneration minimally invasive surgery without use of a videoscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided tissue regeneration surgery
Description: Conventional guided tissue regeneration surgery for periodontal regeneration without use of a videoscope
Study: NCT05732909

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-β-hydroxybutyrate/D 1,3 butanediol monoester
Description: Ketone monoester

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-β-hydroxybutyrate/D 1,3 butanediol monoester
Description: Ketone monoester
Study: NCT06079463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive relaxation exercise
Description: Step 1: Take a comfortable position (sitting or lying down) and wear comfortable, non-tightening clothes.~Step 2: Try to relax with eyes closed, without focusing on thoughts, by focusing on your own body muscles.~Step 3: Right and left, respectively, hands, arms (triceps muscle), chest, abdomen, hips, legs (thigh muscles), feet and toes, neck, shoulder (scapula muscles) and muscle groups on the face (around the eyes, chin) and eyebrow muscles) by concentrating on contracting and relaxing these muscles.~Step 4: Focusing on the muscle groups of the whole body, contracting and relaxing.~Step 5: Opening the eyes slowly, trying to feel the feeling of comfort in the body (Turkish Psychologists Association Progressive Relaxation Exercises).
Study: NCT06577714

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Electromechanical wave imaging (EWI)
Description: EWI is a high-frame rate ultrasound technique that images the electromechanical wave corresponding to the propagation of the onset of myocardial contraction in response to electrical activation, namely electromechanical coupling.
Study: NCT06235801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Given by PO
Study: NCT06052241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: shampoos and scalp serums
Description: shampoos and scalp serums personalized according to their SPI-AI-defined scalp types
Study: NCT06198465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil
Description: adebrelimab: 1200mg，D1，q3w; Paclitaxel: 50mg/m2 D1/8/15； Lobaplatin: 50mg，iv 2h，d1; Fluorouracil: 400mg/m2，bolus iv，600mg/m2，iv 22h，d1-3；
Study: NCT05988996

Intervention type: BEHAVIORAL
Intervention: Participant guided peer support gathering
Description: This prospective observational cohort study will be assessing parental stress, anxiety, and sense of belonging before and after participant attendance at the culturally concordant peer group session.

Intervention type: BEHAVIORAL
Intervention: Participant guided peer support gathering
Description: This prospective observational cohort study will be assessing parental stress, anxiety, and sense of belonging before and after participant attendance at the culturally concordant peer group session.

Intervention type: BEHAVIORAL
Intervention: Participant guided peer support gathering
Description: This prospective observational cohort study will be assessing parental stress, anxiety, and sense of belonging before and after participant attendance at the culturally concordant peer group session.
Study: NCT01512901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Microsphere (DE-102） Low Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Microsphere (DE-102） High Dose

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Study: NCT03584737

Intervention type: DIAGNOSTIC_TEST
Intervention: rapid in vitro diagnostic test
Description: IVD for qualitative detection of 3 bacterial pathogens (Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae)
Study: NCT05431075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Included in quadruple eradication medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Included in quadruple eradication medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline tid
Description: Included in quadruple eradication medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline qid
Description: Included in quadruple eradication medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium Citrate
Description: Included in quadruple eradication medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Included in quadruple eradication medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal Bismuth Pectin
Description: Included in quadruple eradication medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal Bismuth Pectin
Description: Included in quadruple eradication medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 20mg
Description: Included in quadruple eradication medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20mg
Description: Included in quadruple eradication medication.
Study: NCT04131608

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC ,Serum ferritin ,HBA1C
Description: Diabetic patients will be applied to CBC, HBA1C and serum ferritin

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC ,Serum ferritin ,HBA1C
Description: Diabetic patients will be applied to CBC, HBA1C and serum ferritin
Study: NCT05560048

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rice protein RP-80N
Description: rice protein RP-80NY were dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rice protein RP-80N
Description: rice protein RP-80NY were dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo were dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo were dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight
Study: NCT06240325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPP
Description: SPP prioritizes increasing sleep duration and regularizing sleep-wake timing. The provider and youth review the youth's sleep pattern, based on sleep diary data collected before and during the program and actigraphy data collected at baseline. They discuss benefits to the current sleep pattern, reasons for changing sleep, and they create an action plan. Psychoeducation about healthy sleep is offered via a handout developed by our group. Youth and provider jointly select SPP strategies relevant to the contributors to poor sleep for each youth (e.g., time management, limiting weekend oversleep). In the second session they review progress and adjust the plan. Parents participate for part of each session to learn about their child's sleep and to discuss ways they can support their child to make the planned changes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Psychoeducation
Description: Using the pamphlet also used in SPP, SPE will present sleep hygiene practices commonly included in sleep education programs and endorsed by national health organizations.
Study: NCT05101629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg, IV, over 30 minutes every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Capsules
Description: Lenvatinib 8 mg for BW \< 60 kg / 12 mg for BW ≥ 60 kg oral, once daily for 3 weeks
Study: NCT06545760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC) support for > 2 days
Description: Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for greater than 2 days prior to discharge home

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Kangaroo mother care (KMC) support for < 2 days
Description: Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for less than 2 days prior to discharge home
Study: NCT05142592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG7236
Description: The IPG7236 drug product is supplied as oral tablet dosage form, containing two strengths: 25 mg and 100 mg, respectively, which contain IPG7236.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG7236
Description: The IPG7236 drug product is supplied as oral tablet dosage form, containing two strengths: 25 mg and 100 mg, respectively, which contain IPG7236.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG7236
Description: The IPG7236 drug product is supplied as oral tablet dosage form, containing two strengths: 25 mg and 100 mg, respectively, which contain IPG7236.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG7236
Description: The IPG7236 drug product is supplied as oral tablet dosage form, containing two strengths: 25 mg and 100 mg, respectively, which contain IPG7236.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG7236
Description: The IPG7236 drug product is supplied as oral tablet dosage form, containing two strengths: 25 mg and 100 mg, respectively, which contain IPG7236.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG7236
Description: The IPG7236 drug product is supplied as oral tablet dosage form, containing two strengths: 25 mg and 100 mg, respectively, which contain IPG7236.
Study: NCT04496219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture Therapy
Description: Undergo acupuncture therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture Therapy
Description: Undergo acupuncture therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Solution
Description: Given by intravesical injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG Solution
Description: Given by intravesical injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care symptom management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care symptom management
Study: NCT04920201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Over-ground walking without GEMS-H
Description: Over-ground walking without GEMS-H (30 min per session, at least 3 times per weeks, total 10 sessions)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Over-ground walking with GEMS-H with resist mode
Description: Over-ground walking with GEMS-H with resist mode (30 min per session, at least 3 times per weeks, total 10 sessions)
Study: NCT04496219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies